These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23227538)

  • 1. [Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
    Yao JW; Sun W; Chen J; Xu WF
    Yao Xue Xue Bao; 2012 Sep; 47(9):1111-9. PubMed ID: 23227538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit.
    Wang M; Xu S; Wu C; Liu X; Tao H; Huang Y; Liu Y; Zheng P; Zhu W
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5450-5454. PubMed ID: 27777009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
    Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
    Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
    Qin AF; Li Y; Song HR; Chen XG; Jin XF; Wang K; Zhang LJ; Huo LC; Feng ZQ
    Yao Xue Xue Bao; 2012 Dec; 47(12):1623-9. PubMed ID: 23460968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Synthesis and biological evaluation of sorafenib thiourea derivatives].
    Yang Z; Fang Z; Wang ZX; Wei P
    Yao Xue Xue Bao; 2011 Sep; 46(9):1093-7. PubMed ID: 22121780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
    Wang K; Li Y; Zhang LJ; Yang HZ; Chen XG; Feng ZQ
    Yao Xue Xue Bao; 2014 May; 49(5):639-43. PubMed ID: 25151734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
    Yao J; He Z; Chen J; Sun W; Fang H; Xu W
    Bioorg Med Chem Lett; 2012 Nov; 22(21):6549-53. PubMed ID: 23021967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.
    El-Damasy AK; Cho NC; Nam G; Pae AN; Keum G
    ChemMedChem; 2016 Aug; 11(15):1587-95. PubMed ID: 27405013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
    Lu CS; Tang K; Li Y; Jin B; Yin DL; Ma C; Chen XG; Huang HH
    Yao Xue Xue Bao; 2013 May; 48(5):709-17. PubMed ID: 23888694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
    Zhong L; Fu XY; Zou C; Yang LL; Zhou S; Yang J; Tang Y; Cheng C; Li LL; Xiang R; Chen LJ; Chen YZ; Wei YQ; Yang SY
    Int J Cancer; 2014 Dec; 135(12):2972-83. PubMed ID: 24789676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
    Hwang SH; Wecksler AT; Zhang G; Morisseau C; Nguyen LV; Fu SH; Hammock BD
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3732-7. PubMed ID: 23726028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
    Wang M; Xu S; Lei H; Wang C; Xiao Z; Jia S; Zhi J; Zheng P; Zhu W
    Bioorg Med Chem; 2017 Oct; 25(20):5754-5763. PubMed ID: 28927801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
    Chen KF; Tai WT; Huang JW; Hsu CY; Chen WL; Cheng AL; Chen PJ; Shiau CW
    Eur J Med Chem; 2011 Jul; 46(7):2845-51. PubMed ID: 21531053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological evaluation of a novel sorafenib analogue, t-CUPM.
    Wecksler AT; Hwang SH; Liu JY; Wettersten HI; Morisseau C; Wu J; Weiss RH; Hammock BD
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):161-71. PubMed ID: 25413440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: design, synthesis, and antiproliferative activity against melanoma cell line.
    Cho HJ; El-Gamal MI; Oh CH; Lee SH; Sim T; Kim G; Choi HS; Choi JH; Yoo KH
    Chem Pharm Bull (Tokyo); 2013; 61(7):747-56. PubMed ID: 23812399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H; Quan H; Lou L
    Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.
    Wu C; Wang M; Tang Q; Luo R; Chen L; Zheng P; Zhu W
    Molecules; 2015 Oct; 20(10):19361-71. PubMed ID: 26512636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, activity and docking studies of phenylpyrimidine-carboxamide Sorafenib derivatives.
    Wang W; Wu C; Wang J; Luo R; Wang C; Liu X; Li J; Zhu W; Zheng P
    Bioorg Med Chem; 2016 Dec; 24(23):6166-6173. PubMed ID: 28340913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.